Skip to main content
Veterinary Medicines

KALAFEV, 50 mg/ml, ενέσιμο διάλυμα για βοοειδή, χοίρους και άλογα

Authorised
  • Flunixin meglumine

Product identification

Medicine name:
KALAFEV, 50 mg/ml, ενέσιμο διάλυμα για βοοειδή, χοίρους και άλογα
Active substance:
  • Flunixin meglumine
Target species:
  • Cattle
  • Horse
  • Pig
Route of administration:
  • Intramuscular use
  • Intravenous use

Product details

Active substance and strength:
  • Flunixin meglumine
    82.95
    milligram(s)
    /
    1.00
    millilitre(s)
Pharmaceutical form:
  • Solution for injection
Withdrawal period by route of administration:
  • Intramuscular use
    • Cattle
      • Meat and offal
        10
        day
      • Milk
        24
        hour
    • Horse
      • Meat and offal
        7
        day
    • Pig
      • Meat and offal
        18
        day
  • Intravenous use
    • Cattle
      • Meat and offal
        10
        day
      • Milk
        24
        hour
    • Horse
      • Meat and offal
        7
        day
    • Pig
      • Meat and offal
        18
        day
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QM01AG90
Authorisation status:
  • Valid
Authorised in:
  • Greece
Available in:
  • Greece
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Marketing authorisation holder:
  • Fatro S.p.A.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Fatro S.p.A.
Responsible authority:
  • National Organization For Medicines
Authorisation number:
  • 69428/18/26-11-2019/K-0186601
Date of authorisation status change:

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
Greek (PDF)
Published on: 20/06/2022
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."